Wave Life Sciences Plans to Seek FDA Approval on Positive Phase 2 DMD Data

Rare Daily Staff

Wave Life Sciences reported positive data from a phase 2 trial of its exon-skipping oligonucleotide for boys with the rare neuromuscular condition Duchenne muscular dystrophy who are amenable to exon 53 skipping.

The study, FORWARD-53, achieved all trial goals, demonstrating sustained and industry-leading exon skipping, muscle concentrations and dystrophin restoration through 48 weeks and a 61-day tissue half-life that supports monthly dosing.

WVE-N531 was safe and well-tolerated through 48 weeks. All treatment-related adverse events were of mild to moderate intensity. There were no serious adverse events and no discontinuations due to any causes.

Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disorder caused predominantly by out-of-frame deletions in the dystrophin gene, resulting in absent or defective dystrophin protein. Dystrophin protein is needed for normal muscle maintenance and operation. Due to the genetic mutations in DMD, the body is unable produce functional dystrophin, which results in progressive and irreversible loss of muscle function, including the heart and lungs. Worldwide, DMD affects approximately one in 5,000 newborn boys. Approximately 8 percent to 10 percent of boys with DMD have mutations amenable to treatment with an exon 53 skipping therapy. Exon skipping aims to address the underlying cause of DMD by promoting the production of dystrophin protein to stabilize or slow disease progression.

WVE-N531 was designed using Wave’s oligonucleotide chemistry modifications, including PN backbone chemistry. WVE-N531 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food & Drug Administration.

Wave is advancing programs for exons 52, 51, 45 and 44, that leverage the same oligonucleotide chemistry, including PN backbone chemistry and stereochemical control, enabling muscle delivery and potency without requiring antibody or peptide conjugates.

Wave said that the company met with the U.S. Food and Drug Administration on WVE-N531 to discuss its interim 24-week data and initial plans for the confirmatory trial, where the Agency confirmed that the accelerated approval pathway using dystrophin expression as a surrogate endpoint remains open.

Based on the FDA feedback and the 48-week data, Wave intends to file a New Drug Application in 2026 for accelerated approval of WVE-N531. The NDA filing will be based on all FORWARD-53 data, which will include additional data to support monthly dosing.

“Despite progress in Duchenne, there remains a significant unmet need for therapeutics that meaningfully impact disease progression. These data demonstrate a promising continuum from dystrophin restoration to regeneration and maturation of muscle tissue, to functional improvement,” said Pat Furlong, founder and president of Parent Project Muscular Dystrophy. “Paired with monthly administration and a continued favorable safety profile, WVE-N531 represents a significant step forward – not just for individuals amenable to exon 53 skipping, but also for the broader exon skipping field.”

Photo: Pat Furlong, founder and president of Parent Project Muscular Dystrophy